Videos

Rani Khetarpal shares how models like OCM can be successful. Utilizing an outcomes-based clinical pathway tool and practice transformation are large factors in the success of the models.

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

February 4, 2021 is #WorldCancerDay! Please join AVBCC Co-Chair Burt Zweigenhaft in sharing your #IAmAndIWill statement and make a pledge to continue to work on improving cancer care across the globe.

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, examine who should be tested for tumor mutations.

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes.

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, confer on the categorization of various cancer types in which NTRK gene fusions may be detected.

Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, identify specific subpopulations of patients in which NTRK gene fusions may be commonly uncovered.

Watch this webinar discussion to hear lessons learned, strategies for success and how integrated technology can deliver proactive insights, help manage costs and ultimately enable successful performance in value-based reimbursement programs.

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explore the mutual and contrasting features of TRK inhibitors.

Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer.